Promedius announced the appointment of Dr. Jean-Yves Reginster as a member of its Scientific Advisory Board (SAB) to advance its global clinical research and commercialization strategy.

Dr. Jean-Yves is a leading osteoporosis authority in Europe, serving as the President of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO), and is a Co-Founder and Board member of the International Osteoporosis Foundation (IOF), where he serves as President of the Committee of National Societies (CNS). He has also been recognized as one of the most prolific researchers in the field, with more than 1,500 publications. It is highly unusual to have a world-renowned scholar like Prof. Jean-Yves Reginster join the SAB of an early-stage startup, which is a testament to the future value and high potential of Promedius.

Promedius’ appointment of Prof. Jean-Yves follows the successful completion of a Series A2 funding round in March, and demonstrates that Promedius, with its CXR-based osteoporosis AI screening solution, is once again being recognized by academia for its innovation and growth potential. Professor Jean-Yves will serve as a bridge between Promedius and global societies, providing insight and guidance on the commercialization strategy for the company's AI solutions in the European market.

Through this collaboration, Promedius will conduct cost-effectiveness studies of its osteoporosis solutions and set the stage for global market entry. In particular, his appointment will allow for stronger networking with European academia and closer collaboration with the PRECCO program, the WHO's five-year bone health initiative. This will play an important role in establishing Promedius as a leading medical AI company in the musculoskeletal field, which is directly related to healthy aging.

"Osteoporosis is asymptomatic, but the fractures it causes can be devastating; for instance, hip fractures carrying a poor prognosis, with a one-year mortality rate higher than some cancers," said Prof. Jean-Yves. "Proper diagnosis is essential to prevent this, but due to the asymptomatic nature of the disease and the limitations of existing diagnostic methods, only 21% of the world's osteoporosis patients are properly diagnosed. "However, Promedius' AI technology for osteoporosis is expected to serve as a gap filler, enabling early screening of suspected patients through opportunistic screening and timely bone density testing, filling the gap in osteoporosis diagnostics, and we are excited to serve as a scientific advisor to Promedius to help realize their vision of 'Healthy Aging through AI'." said Dr. Jean-Yves.

"We are honored to have Prof. Jean-Yves as our Scientific Advisor, and his outstanding expertise and multidisciplinary experience will help us rapidly integrate our innovative technology into the existing healthcare system," said Dr. Hyunjin Bae, CEO of Promedius. "We look forward to this collaboration to further our impact as a screening tool to benefit clinicians and patients around the world."